Literature DB >> 15514478

Glycosphingolipidoses: beyond the enzymatic defect.

Annick Raas-Rothschild1, Irene Pankova-Kholmyansky, Yaacov Kacher, Anthony H Futerman.   

Abstract

The glycosphingolipid lysosomal storage diseases are a group of monogenic human disorders caused by the impaired catalytic activity of enzymes responsible for glycosphingolipid catabolism. Clinical presentation of the diseases is heterogeneous, with little obvious correlation between the kind of accumulating glycosphingolipid and disease progression or pathogenesis. In this review, we discuss clinical symptoms of this group of diseases, and attempt to link disease progression and pathology with the biochemical and cellular pathways that may be potentially altered in the diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15514478     DOI: 10.1023/B:GLYC.0000046272.38480.ef

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  37 in total

Review 1.  New directions in the treatment of Gaucher disease.

Authors:  Anthony H Futerman; Joel L Sussman; Mia Horowitz; Israel Silman; Ari Zimran
Journal:  Trends Pharmacol Sci       Date:  2004-03       Impact factor: 14.819

Review 2.  The molecular biology of apoptosis.

Authors:  D L Vaux; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 3.  The roles of ceramide and complex sphingolipids in neuronal cell function.

Authors:  Rosaria Buccoliero; Anthony H Futerman
Journal:  Pharmacol Res       Date:  2003-05       Impact factor: 7.658

4.  Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.

Authors:  J Tohyama; Y Oya; T Ezoe; M T Vanier; H Nakayasu; N Fujita; K Suzuki
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

5.  Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.

Authors:  Rachel Myerowitz; Douglas Lawson; Hiroki Mizukami; Yide Mi; Cynthia J Tifft; Richard L Proia
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

6.  Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses.

Authors:  L S Finn; M Zhang; S H Chen; C R Scott
Journal:  Am J Med Genet       Date:  2000-03-20

7.  Prevalence of lysosomal storage diseases in Portugal.

Authors:  Rui Pinto; Carla Caseiro; Manuela Lemos; Lurdes Lopes; Augusta Fontes; Helena Ribeiro; Eugénia Pinto; Elisabete Silva; Sónia Rocha; Ana Marcão; Isaura Ribeiro; Lúcia Lacerda; Gil Ribeiro; Olga Amaral; M C Sá Miranda
Journal:  Eur J Hum Genet       Date:  2004-02       Impact factor: 4.246

8.  Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Hum Genet       Date:  2004-06-04       Impact factor: 3.172

9.  Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.

Authors:  Dori Pelled; Emyr Lloyd-Evans; Christian Riebeling; Mylvaganam Jeyakumar; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2003-05-19       Impact factor: 5.157

Review 10.  Insights into the diagnosis and treatment of lysosomal storage diseases.

Authors:  David A Wenger; Stephanie Coppola; Shu-Ling Liu
Journal:  Arch Neurol       Date:  2003-03
View more
  15 in total

Review 1.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

Review 2.  PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism.

Authors:  Florence Bourquin; Guido Capitani; Markus Gerhard Grütter
Journal:  Protein Sci       Date:  2011-09       Impact factor: 6.725

3.  Screening and optimization of ligand conjugates for lysosomal targeting.

Authors:  Igor Meerovich; Alexander Koshkaryev; Ritesh Thekkedath; Vladimir P Torchilin
Journal:  Bioconjug Chem       Date:  2011-10-06       Impact factor: 4.774

4.  Quality of life of brazilian patients with Gaucher disease and fabry disease.

Authors:  Fabiane Lopes Oliveira; Taciane Alegra; Alicia Dornelles; Bárbara Corrêa Krug; Cristina B O Netto; Neusa Sica da Rocha; Paulo D Picon; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2012-04-18

Review 5.  Roles for sphingolipids in Saccharomyces cerevisiae.

Authors:  Robert C Dickson
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 6.  Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function.

Authors:  L Ashley Cowart; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2006-08-10

Review 7.  Sphingolipid regulation of ezrin, radixin, and moesin proteins family: implications for cell dynamics.

Authors:  Mohamad Adada; Daniel Canals; Yusuf A Hannun; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2013-07-12

8.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 9.  Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Authors:  Maria Fuller
Journal:  Lipids Health Dis       Date:  2010-10-11       Impact factor: 3.876

Review 10.  Thematic review series: sphingolipids. New insights into sphingolipid metabolism and function in budding yeast.

Authors:  Robert C Dickson
Journal:  J Lipid Res       Date:  2008-02-23       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.